PA5-62772

antibody from Invitrogen Antibodies

Targeting: OTUD6A DUBA2, FLJ25831, HSHIN6

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-62772

Provider

Invitrogen Antibodies

Product name

OTUD6A Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: HRQELEKFQD DSSIESVVED LAKMNLENRP PRSSKAHRKR ERMESEERER QESIFQAEMS EHLAGFKREE E

Concentration

0.2 mg/mL

References

Submitted references

OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR.

Fu X, Zhao J, Yu G, Zhang X, Sun J, Li L, Yin J, Niu Y, Ren S, Zhu Y, Xu B, Huang L
Communications biology 2022 Mar 1;5(1):182

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of OTUD6A in control (vector only transfected HEK293T lysate) and OTUD6A over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells). Samples were probed using a OTUD6A Polyclonal Antibody (Product # PA5-62772).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of OTUD6A in human testis using OTUD6A Polyclonal Antibody (Product # PA5-62772) shows high expression.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of OTUD6A in human endometrium using OTUD6A Polyclonal Antibody (Product # PA5-62772) shows low expression as expected.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 OTUD6A oligonucleotides markedly suppress prostate tumorigenesis derived from Pten PC-/- mice and patient-derived xenograft (PDX) models. a, b Established Pten PC-/- male mice were injected with AAV-GFP or AAV-sh OTUD6A into VP tissues at 2-month-age. Three months later, VP part of prostates were imaged ( a ) and weighted ( b ) ( n = 5-6). The Pten fl/fl mice were used as the negative control. Data represented the mean +- SEM. c H&E-stained sections of representative VP tissues, scale bars: 100 mum. d IB analysis of PTEN and OTUD6A in different mouse prostates. e - g The PCa PDX model was constructed and the PDX tumor tissues were subcutaneously injected into the flank of 6-week-old NOD/SCID mice, and then AAV-GFP or AAV-sh OTUD6A were intratumorally administrated. The growth curves were shown in ( e ), and the mean tumor growth inhibition rate (TGI) of each monitoring point was shown in ( f ). The dissected tumors were collected and weighed ( g ) around 4 weeks later ( n = 6). Data represented the mean +- SEM. Statistical significance was determined by two-tailed unpaired Student's t -test, * P < 0.05, ** P < 0.01, *** P < 0.001. h Equal amounts of proteins from tumor tissues were evaluated for OTUD6A.